Myriel Pharmaceuticals

Myriel Pharmaceuticals is a clinical-stage biotechnology company dedicated to the development of next-generation therapeutics for psychiatric and neurological conditions. The company's lead program, MYR-101, is being evaluated for the treatment of Treatment-Resistant Depression (TRD), aiming to provide rapid and sustained relief for patients who have failed multiple lines of therapy. Myriel's strategy involves optimizing known pharmacological pathways to improve safety, efficacy, and patient access. The company is led by a management team with a proven track record in CNS drug discovery and global regulatory approvals, including key figures involved in the development of esketamine. Myriel focuses on addressing the significant unmet needs of patients suffering from severe mood disorders through innovative small molecule chemistry. Headquartered in Princeton, New Jersey, the company operates at the intersection of deep neuroscience expertise and efficient clinical execution.